Drug Profile
Research programme: bifunctional short hairpin RNA cancer therapeutics - Gradalis/Baylor College of Medicine
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Baylor College of Medicine; Gradalis
- Developer Baylor College of Medicine
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 11 Jul 2012 Early research in Cancer in USA (unspecified route)